Eli Lilly's experimental weight-loss drug delivers results that match or exceed bariatric surgery, according to trial data presented at a major medical conference. The medication produces substantially greater weight reduction than existing GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro).
Participants taking Lilly's drug lost an average of 36 percent of their body weight over 88 weeks. That performance rivals gastric bypass procedures, which typically produce 25 to 35 percent weight loss. Current GLP-1 medications achieve roughly 15 to 22 percent reduction in most users.
The drug works through a novel triple-hormone mechanism. It simultaneously activates receptors for glucagon, GLP-1, and glucose-dependent insulinotropic peptide (GIP). This three-pronged approach appears more powerful than dual-hormone medications currently on the market.
Researchers observed improvements beyond the scale. Patients showed reductions in blood pressure, cholesterol, and blood sugar levels. Liver fat content decreased significantly. These changes suggest the drug addresses metabolic dysfunction at a fundamental level, not just appetite suppression.
Side effects remain a consideration. Gastrointestinal issues including nausea, vomiting, and diarrhea occurred more frequently in treatment groups than placebo. Some participants discontinued the drug due to tolerability concerns. Long-term safety data is still being collected.
Lilly expects regulatory review to proceed over the next two years. If approved, the medication could transform obesity treatment options. People currently choosing between GLP-1 injections and surgical intervention would gain a more powerful pharmaceutical alternative.
The finding reflects a broader shift in how medicine approaches weight management. Rather than viewing excess weight as simply a behavior problem, researchers